Duncan Hall speaking at MCC Clinical Trial Risk & Performance Management Summit

Duncan Hall, TRI CEO and founder, is a panellist at the MCC Clinical Trial Risk & Performance Management Summit.  Duncan is taking part in the session on Risk Management Emerging Practices and the Impact of ICHE6(R2) Updates which covers the following topics:

  • Current risk assessment practices
  • Challenges with risk tools released prior to ICHE6(R2)
  • Realigning methodologies to support review of critical data and critical processes

To find out more about the event, please go to https://www.fdanews.com/ctriskperformancemngmntsummit